专题笔谈

肠道菌群参与异基因造血干细胞移植免疫重建调控的研究进展

  • 陆海洋 ,
  • 赵维莅 ,
  • 胡晓霞
展开
  • 上海交通大学医学院附属瑞金医院转化医学中心 (上海 200025 )
胡晓霞,主任医师,博士研究生导师。任上海交通大学医学院附属瑞金医院血液科副主任,从事造血干细胞移植的基础和临床研究。担任中国生理学会血液生理学专业委员会委员和中国抗癌协会第六届血液肿瘤专业委员会委员。获得上海市杰出青年医学人才、上海市卫生系统优秀学科带头人和上海市卫生系统优秀青年人才等称号。以第一作者或通信作者(含共同)先后在《Blood》、《Journal of Clinical Investigation》、《Leukemia》等血液学杂志发表论文40余篇,以第二完成人获得上海市科技进步一等奖。

收稿日期: 2024-07-18

  网络出版日期: 2025-03-20

基金资助

国家重点研发计划(2022YFC2502600);国家自然科学基金项目(81710160);上海市“医苑新星”杰出青年医学人才培养计划(20224Z0022)

Gut microbiota modulates immune reconstitution in allogeneic hematopoietic stem cell transplantation

  • Haiyang LU ,
  • Weili ZHAO ,
  • Xiaoxia. HU
Expand
  • National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China

Received date: 2024-07-18

  Online published: 2025-03-20

摘要

肠道菌群作为人体共生的微生物群体,其组成和功能影响人体代谢、免疫、内分泌等多方面生理功能。肠道菌群在异基因造血干细胞移植患者造血和免疫系统的精细调控上也发挥重要作用。在造血功能上,肠道菌群可以通过NOD1-STATs信号、TLRs-MyD88信号等通路调控造血干细胞向多谱系血细胞的分化,并在应激压力下推动造血干细胞向粒-单核系快速分化和成熟。因此,移植早期的原发性植入功能不良可能与肠道菌群功能紊乱有关。在免疫重建上,肠道菌群促进小肠上皮表达抗原递呈分子,是肠道aGVHD的重要始动因素。其次,肠道菌群可通过短链脂肪酸、胆汁酸、吲哚衍生物调节肠道免疫功能,其功能失调可导致肠道黏液屏障和免疫屏障功能紊乱,进一步促进肠道aGVHD发生和发展。因此,靶向肠道菌群成为一种有效的治疗策略,逐渐开始应用于临床。其中,粪便菌群移植联合传统抗排异治疗,可显著改善SR-aGVHD的临床严重程度和预后,其安全性高,不良反应可控,是SR-aGVHD治疗的新突破口。

本文引用格式

陆海洋 , 赵维莅 , 胡晓霞 . 肠道菌群参与异基因造血干细胞移植免疫重建调控的研究进展[J]. 实用医学杂志, 2025 , 41(5) : 628 -633 . DOI: 10.3969/j.issn.1006-5725.2025.05.002

Abstract

As a symbiotic microbial community within the human body, the gut microbiota plays a crucial role in modulating various physiological processes, including metabolism, immunity, and endocrine function. During allogeneic hematopoietic stem cell transplantation (allo-HSCT), the hematopoietic and immune systems undergo significant changes, which are also influenced by the gut microbiota. Specifically, regarding hematopoietic function, the gut microbiota facilitates the multi-lineage differentiation of hematopoietic stem cells via NOD1-STATs and TLRs-MyD88 signaling pathways, and promotes rapid granulomonocytic lineage differentiation under infection stress. Consequently, early-stage primary graft dysfunction following transplantation may be associated with gut microbiota dysbiosis. In terms of immune function, the gut microbiota enhances the expression of antigen-presenting molecules on intestinal epithelial cells, thereby initiating acute graft-versus-host disease (aGVHD) in the gastrointestinal tract. Moreover, the gut microbiota regulates intestinal immune function through metabolites such as short-chain fatty acids, bile acids, and indole derivatives. Dysbiosis of the gut microbiota can lead to disruption of the intestinal mucus barrier and immune barrier functions, further promoting the onset and progression of aGVHD in the gastrointestinal tract. Therefore, targeting the gut microbiota has emerged as an attractive therapeutic strategy and has been clinically applied. Notably, fecal microbiota transplantation combined with immunosuppressive therapy has shown significant efficacy in alleviating clinical severity and improving prognosis in steroid-refractory aGVHD, demonstrating high safety and manageable adverse reactions, representing a novel breakthrough in its treatment.

参考文献

1 章新郑. 2005—2020年中国国家及分省疾病监测点的肿瘤死亡疾病负担数据解读 [J]. 诊断学理论与实践, 2024, 23(4): 371-377.
2 SHONO Y, VAN DEN BRINK M R M. Gut microbiota injury in allogeneic haematopoietic stem cell transplantation [J]. Nat Rev Cancer, 2018, 18(5): 283-295. doi:10.1038/nrc.2018.10
3 JOSEFSDOTTIR K S, BALDRIDGE M T, KADMON C S, et al. Antibiotics impair murine hematopoiesis by depleting the intestinal microbiota [J]. Blood, 2017, 129(6): 729-739. doi:10.1182/blood-2016-03-708594
4 YAN H, WALKER F C, ALI A, et al. The bacterial microbiota regulates normal hematopoiesis via metabolite-induced type 1 interferon signaling [J]. Blood Advances, 2022, 6(6): 1754-1765. doi:10.1182/bloodadvances.2021006816
5 IWAMURA C, BOULADOUX N, BELKAID Y, et al. Sensing of the microbiota by NOD1 in mesenchymal stromal cells regulates murine hematopoiesis [J]. Blood, 2017, 129(2): 171-176. doi:10.1182/blood-2016-06-723742
6 KHOSRAVI A, Yá?EZ A, PRICE J G, et al. Gut microbiota promote hematopoiesis to control bacterial infection [J]. Cell Host Microbe, 2014, 15(3): 374-381. doi:10.1016/j.chom.2014.02.006
7 JACKSON W D, GIACOMASSI C, WARD S, et al. TLR7 activation at epithelial barriers promotes emergency myelopoiesis and lung antiviral immunity [J]. Elife, 2023, 12:e85647. doi:10.7554/elife.85647
8 中华医学会血液学分会干细胞应用学组. 异基因造血干细胞移植急性移植物抗宿主病诊断与治疗中国专家共识(2024年版) [J]. 中华血液学杂志, 2024, 45(6): 525-533. doi:10.3760/cma.j.cn121090-20240608-00214
9 KOYAMA M, MUKHOPADHYAY P, SCHUSTER I S, et al. MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota [J]. Immunity, 2019, 51(5): 885-98.e7. doi:10.1016/j.immuni.2019.08.011
10 KOYAMA M, HIPPE D S, SRINIVASAN S, et al. Intestinal microbiota controls graft-versus-host disease independent of donor-host genetic disparity [J]. Immunity, 2023, 56(8): 1876-93.e8. doi:10.1016/j.immuni.2023.06.024
11 赖静, 傅鑫, 李成龙,等. 异基因造血干细胞移植后患者口腔及肠道菌群与早期胃肠道急性移植物抗宿主病的关系 [J]. 陆军军医大学学报, 2024, 46(4): 331-339. doi:10.16016/j.2097-0927.202310041
12 KAWAGUCHI K, UMEDA K, HIEJIMA E, et al. Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation [J]. Int J Hematol, 2018, 108(1): 66-75. doi:10.1007/s12185-018-2442-2
13 MINCULESCU L, MARQUART H V, RYDER L P, et al. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation [J]. Front Immunol, 2019, 10: 1997. doi:10.3389/fimmu.2019.01997
14 STECK N, HOFFMANN M, SAVA I G, et al. Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation [J]. Gastroenterology, 2011, 141(3): 959-971. doi:10.1053/j.gastro.2011.05.035
15 HAYASE E, HAYASE T, JAMAL M A, et al. Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease [J]. Cell, 2022, 185(20): 3705-3719.e14. doi:10.1016/j.cell.2022.09.007
16 SHONO Y, DOCAMPO M D, PELED J U, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice [J]. Sci Transl Med, 2016, 8(339): 339ra71. doi:10.1126/scitranslmed.aaf2311
17 高艳林, 王风霞, 张雅文, 等. 异基因造血干细胞移植后发生胃肠道急性移植物抗宿主病的危险因素分析 [J]. 医学研究杂志, 2024, 53(5): 138-143.
18 HEIMESAAT M M, NOGAI A, BERESWILL S, et al. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease [J]. Gut, 2010, 59(8): 1079-1087. doi:10.1136/gut.2009.197434
19 ZHAO Y, LIU Q, YANG L, et al. TLR4 inactivation protects from graft-versus-host disease after allogeneic hematopoietic stem cell transplantation [J]. Cell Mol Immunol, 2013, 10(2): 165-175. doi:10.1038/cmi.2012.58
20 陈晓欢, 洪学志, 刘雷,等. 肠道菌群失调与类风湿性关节炎 [J]. 实用医学杂志, 2019, 35(16): 2664-2668. doi:10.3969/j.issn.1006-5725.2019.16.033
21 徐晓蓉, 龚坚, 王婧,等. 肠道菌群与银屑病相关性的实验研究进展 [J]. 实用医学杂志, 2020, 36(9): 566-569.
22 YAO K, XIE Y, WANG J, et al. Gut microbiota: A newly identified environmental factor in systemic lupus erythematosus [J]. Front Immunol, 2023, 14: 1202850. doi:10.3389/fimmu.2023.1202850
23 杨艳青, 李灿委, 杨自忠,等. 肠道菌群代谢物——短链脂肪酸的研究进展 [J]. 实用医学杂志, 2022, 38(14): 1834-1837. doi:10.3969/j.issn.1006
24 FUSCO W, LORENZO M B, CINTONI M, et al. Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota [J]. Nutrients, 2023, 15(9): 2211. doi:10.3390/nu15092211
25 LIANG L, LIU L, ZHOU W, et al. Gut microbiota-derived butyrate regulates gut mucus barrier repair by activating the macrophage/WNT/ERK signaling pathway [J]. Clin Sci (Lond), 2022, 136(4): 291-307. doi:10.1042/cs20210778
26 CHEN G, RAN X, LI B, et al. Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model [J]. EBioMedicine, 2018, 30: 317-325. doi:10.1016/j.ebiom.2018.03.030
27 LI G, LIN J, ZHANG C, et al. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease [J]. Gut Microbes, 2021, 13(1): 1968257. doi:10.1080/19490976.2021.1968257
28 FURUSAWA Y, OBATA Y, FUKUDA S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells [J]. Nature, 2013, 504(7480): 446-450. doi:10.1038/nature12721
29 STEIN-THOERINGER C K, NICHOLS K B, LAZRAK A, et al. Lactose drives Enterococcus expansion to promote graft-versus-host disease [J]. Science, 2019, 366(6469): 1143-1149.
30 FUCHS C D, TRAUNER M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology [J]. Nat Rev Gastroenterol Hepatol, 2022, 19(7): 432-450. doi:10.1038/s41575-021-00566-7
31 杨瑾, 韦瑶, 金钧. 胆汁酸与肠道菌群的相互作用及对脓毒症的影响 [J]. 内科理论与实践, 2024, 19(3): 207-211. doi:10.16138/j.1673-6087.2024.03.11
32 PAIK D, YAO L, ZHANG Y, et al. Human gut bacteria produce Τ(Η)17-modulating bile acid metabolites [J]. Nature, 2022, 603(7903): 907-912. doi:10.1038/s41586-022-04480-z
33 SONG X, SUN X, OH S F, et al. Microbial bile acid metabolites modulate gut RORγ(+) regulatory T cell homeostasis [J]. Nature, 2020, 577(7790): 410-415. doi:10.1038/s41586-019-1865-0
34 LINDNER S, MILTIADOUS O, RAMOS R J F, et al. Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease [J]. Nat Microbiol, 2024, 9(3): 614-630. doi:10.1038/s41564-024-01617-w
35 AGUS A, PLANCHAIS J, SOKOL H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease [J]. Cell Host Microbe, 2018, 23(6): 716-724. doi:10.1016/j.chom.2018.05.003
36 XUE C, LI G, ZHENG Q, et al. Tryptophan metabolism in health and disease [J]. Cell Metab, 2023, 35(8): 1304-1326. doi:10.1016/j.cmet.2023.06.004
37 LI K, HAO Z, DU J, et al. Bacteroides thetaiotaomicron relieves colon inflammation by activating aryl hydrocarbon receptor and modulating CD4(+)T cell homeostasis [J]. Int Immunopharmacol, 2021, 90: 107183. doi:10.1016/j.intimp.2020.107183
38 ZENG C, CHENG T T, MA X, et al. The absence of AhR in CD4(+) T cells in patients with acute graft-versus-host disease may be related to insufficient CTCF expression [J]. Clin Epigenetics, 2022, 14(1): 109. doi:10.1186/s13148-022-01330-7
39 HAN L, ZHAO K, LI Y, et al. A gut microbiota score predicting acute graft-versus-host disease following myeloablative allogeneic hematopoietic stem cell transplantation [J]. Am J Transplant, 2020, 20(4): 1014-1027. doi:10.1111/ajt.15654
40 MARKEY K A, SCHLUTER J, GOMES A L C, et al. The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD [J]. Blood, 2020, 136(1): 130-136. doi:10.1182/blood.2019003369
41 WANG Y, HUANG L, HUANG T, et al. The Gut Bacteria Dysbiosis Contributes to Chronic Graft-Versus-Host Disease Associated With a Treg/Th1 Ratio Imbalance [J]. Front Microbiol, 2022, 13: 813576. doi:10.3389/fmicb.2022.813576
42 MUKHERJEE A, LORDAN C, ROSS R P, et al. Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health [J]. Gut Microbes, 2020, 12(1): 1802866. doi:10.1080/19490976.2020.1802866
43 VALLET N, SALMONA M, MALET-VILLEMAGNE J, et al. Circulating T cell profiles associate with enterotype signatures underlying hematological malignancy relapses [J]. Cell Host Microbe, 2023, 31(8): 1386-1403.e6. doi:10.1016/j.chom.2023.06.009
44 VALLET N, LE GRAND S, BONDEELLE L, et al. Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation [J]. Blood, 2022, 140(23): 2500-2513. doi:10.1182/blood.2022016926
45 SOFI M H, WU Y, TICER T, et al. A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD [J]. JCI Insight, 2021, 6(3): e136841. doi:10.1172/jci.insight.136841
46 VOSSEN J M, GUIOT H F, LANKESTER A C, et al. Complete suppression of the gut microbiome prevents acute graft-versus-host disease following allogeneic bone marrow transplantation [J]. PLoS One, 2014, 9(9): e105706. doi:10.1371/journal.pone.0105706
47 ROUTY B, LETENDRE C, ENOT D, et al. The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation [J]. Oncoimmunology, 2017, 6(1): e1258506. doi:10.1080/2162402x.2016.1258506
48 SEVERYN C J, SIRANOSIAN B A, KONG S T, et al. Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation [J]. JCI Insight, 2022, 7(7): e154344. doi:10.1172/jci.insight.154344
49 KHUAT L T, LE C T, PAI C S, et al. Obesity induces gut microbiota alterations and augments acute graft-versus-host disease after allogeneic stem cell transplantation [J]. Sci Transl Med, 2020, 12(571): eaay7713. doi:10.1126/scitranslmed.aay7713
50 HOLMES Z C, TANG H, LIU C, et al. Prebiotic galactooligosaccharides interact with mouse gut microbiota to attenuate acute graft-versus-host disease [J]. Blood, 2022, 140(21): 2300-2304. doi:10.1182/blood.2021015178
51 JENQ R R, UBEDA C, TAUR Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation [J]. J Exp Med, 2012, 209(5): 903-911. doi:10.1084/jem.20112408
52 唐晓文, 吴德沛. 我如何用粪菌移植治疗肠道急性移植物抗宿主病 [J]. 中华血液学杂志, 2022, 43(5): 365-369.
53 KAKIHANA K, FUJIOKA Y, SUDA W, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut [J]. Blood, 2016, 128(16): 2083-2088. doi:10.1182/blood-2016-05-717652
54 LIU Y, ZHAO Y, QI J, et al. Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD [J]. Exp Hematol Oncol, 2022, 11(1): 96. doi:10.1186/s40164-022-00350-6
55 BILI?SKI J, JASI?SKI M, BASAK G W. The Role of Fecal Microbiota Transplantation in the Treatment of Acute Graft-versus-Host Disease [J]. Biomedicines, 2022, 10(4): 837. doi:10.3390/biomedicines10040837
文章导航

/